Advertisement
Lipella Pharmaceuticals Inc saw a strong rally over the past five days, rising 0.37 USD, or 13.70%, to close at 3.07 USD on February 7 at 7:59 PM GMT-5. Even after ending Friday with a red signal, the stock skyrocketed after it received FDA approval for an expanded access program for LP-310 in Oral Lichen Planus.
During the latest trading session, Lipella Pharmaceuticals opened at 4.16 USD, marking its highest level of the session. However, selling pressure pushed the stock down to an intraday low of 2.92 USD before stabilizing at 3.07 USD by the close.
After-hours trading saw an additional surge, with the stock climbing 0.13 USD, or 4.23%, to 3.20 USD. Lipella Pharmaceuticals maintained a market capitalization of 37.11L, highlighting its relatively smaller size compared to larger pharmaceutical firms. The stock faced resistance near 4.16 USD,which intensified selling pressure, while support at a low of 2.92 USD helped stabilize its price.
Disclaimer: This article is for informational purposes only and does not constitute any financial advice.